Navigation Links
New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
Date:5/15/2008

ecifically designed to target and

block the function of HER2, which causes fast growing, aggressive

breast cancer tumours. Herceptin delivers high cure rates for women

with HER2 positive early breast cancer and extends survival across all

stages of HER2 positive breast cancer by activating the immune system

and suppressing HER2. Herceptin is considered the foundation of care in

women with HER2-positive breast cancer and is recommended in treatment

guidelines throughout the world.

-- Colorectal cancer is the most common cancer in developed countries(4)

and the second most common cause of death from cancer across all cancer

types in men and women across Europe.(5)

-- Avastin acts by blocking VEGF, the key mediator of tumor angiogenesis,

offering patients a better chance of significantly improved survival.

Avastin is the first anti-angiogenic inhibitor to increase survival in

first and second line treatment and to provide significant improvements

in the time that patients can live without their disease advancing.

The 2008 ASCO Annual Meeting takes place from May 31 to June 3, McCormick Place, Chicago, Illinois, USA. Full details can be found at http://www.asco.org .

If you or your media colleagues are interested in attending the Roche Media Event during ASCO on 30th May, where the data outlined in brief above will be presented, please contact Anne Cameron (see details below).

References:

1. Wilking N and Jonsson B. A Pan-European comparison regarding patient

access to cancer drugs. Karolinska Institute in collaboration with

Stockholm School of Economics, Stockholm, Sweden, 2005

2. World Health Organisation (WHO) 2003.

http://www.who.int/mediacentre/releases/20
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
3. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
4. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
9. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
10. Roche responds to announcement of IDEAL hepatitis C trial results
11. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2008)...NAA says: Wrong Question Asked. Wrong Children Stu.... 3 /PRNewswire-USNewswire/ -- A Centers for Disea...ay claims there is no link,between the MMR vaccine...,says this study does nothing to dispel the growin...and raises several questions concerning design,and...
(Date:9/3/2008)... - Long term follow up results from chronically in...xceed positive data obtained earlier in 2008, - ...cant and long-term antiviral effect of ther... way and strongly support move into a second gener...nt IC31(R) acting through TLR ...
(Date:9/3/2008)... GAITHERSBURG, Md., Sept. 3 /- Panace...ce of U.S. Patent Number 7,413,737 covering,antibo...roxylase (HAAH), a,proprietary human cancer biomar...developed in collaboration with the Massachusetts ...usive, worldwide rights to this patent,for develop...
(Date:9/3/2008)... Company Focuses Operations, Updates Zingo Launch ...ation Strategy Conference Call To...Sept. 3 /- Anesiva,Inc. (N...ll restructure,operations to focus on commercial a...s transition to a specialty pharmaceutical pain ma...
Breaking Medicine Technology:CDC Misses Target With Flawed MMR/Autism Study 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5ZONARE Names Marcotte Chief Financial Officer 4588 1ZONARE Names Marcotte Chief Financial Officer 4588 2New Survey Shows Majority of Employers Rank Smoking as One of Their Greatest Priority Health Issues But Only 2 Percent Provide Comprehensive Smoking 4584 1New Survey Shows Majority of Employers Rank Smoking as One of Their Greatest Priority Health Issues But Only 2 Percent Provide Comprehensive Smoking 4584 2New Survey Shows Majority of Employers Rank Smoking as One of Their Greatest Priority Health Issues But Only 2 Percent Provide Comprehensive Smoking 4584 3New Survey Shows Majority of Employers Rank Smoking as One of Their Greatest Priority Health Issues But Only 2 Percent Provide Comprehensive Smoking 4584 4New Survey Shows Majority of Employers Rank Smoking as One of Their Greatest Priority Health Issues But Only 2 Percent Provide Comprehensive Smoking 4584 5Leading Edge Research Underway in Fall Prevention for Seniors 1502 1Leading Edge Research Underway in Fall Prevention for Seniors 1502 2Leading Edge Research Underway in Fall Prevention for Seniors 1502 3Genzyme and Sunway to Collaborate on Gene Therapy Program in China 1498 1Genzyme and Sunway to Collaborate on Gene Therapy Program in China 1498 2Genzyme and Sunway to Collaborate on Gene Therapy Program in China 1498 3Genzyme and Sunway to Collaborate on Gene Therapy Program in China 1498 4
...age of More Than Two Hours Per Day, RESEARCH TRIAN...ing the once daily, investigational medication REQ...lease Tablets to,Parkinson,s patients, existing le..., time, allowing patients to continue,their daily ...,describes the return of Parkinson,s symptoms as a...
...ppresses Amyloid Plaque Formation, ANNAPOLIS, Md.,... a leading biodefense company specializing in the ...ermeasures against chemical,and biological terrori...nant butyrylcholinesterase (rBChE) research progra... Conference on,Alzheimer,s and Parkinson,s Disease...
Other Medicine Technology:Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 2Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 3Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 4Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 5PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 2PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 3PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 4PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 5PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 6
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...on is putting his best foot forward with respect t...ions are rife for the parties’ annual spring// con...terated that curtailing health problems like obesi...and the risk of sexually transmitted diseases is v...
...ch age of modern medicine, could it be possible to...ugh the power //of meditation? According to a stud...technique can significantly reduce the severity of...lts of this study indicate that transcendental med...
... insulin therapy on the medical-surgical wards res...dividualized management// in patients with diabeti...may be possible. “This is the first randomized ... subcutaneous insulin protocol on medical-surgical...
...c, which is present in every part of the body, cou...study that could help// in the development of new ...ribute to the formation of plaques in the brains o... disease. It is also vital for the healthy working...
Other Medicine News:Health News:Transcendental Meditation Can Help 2Health News:New Research May Pave the Way for Shorter Hospital Stays for Diabetes Patients 2
The HYRYS™ 2 densitometer is reflective of Sebia's expertise in the development and design of imaging systems and densitometers utilized in the electrophoresis field.
Hydragel K20 is Sebia's quality line of manual agarose gel electrophoresis products. Samples are applied utilizing the same patented applicator combs that is used for sample application on the HYDRAS
Eliminating the need for any manual pipetting, the HydraPLUS delivers precise micro-volumes of sample directly from primary tubes to four HYDRASYS sample applicators contained in a built-in humidity
Handheld Digital Retinal Camera
Medicine Products: